Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150887 · ClinicalTrials.gov registry record · Phase 1
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
A Phase 1 study of Leukemia, Myeloid, Acute, sponsored by OncoVerity.
- Active
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT04150887: Active Phase 1 study of Leukemia, Myeloid, Acute, sponsored by OncoVerity.
NCT04150887 is a Phase 1 study of Leukemia, Myeloid, Acute that is active but no longer recruiting, run by OncoVerity. The registered enrollment target is 61 participants, below the 114-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04150887, a Phase 1 study of Leukemia, Myeloid, Acute, is active but no longer recruiting, sponsored by OncoVerity.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
Primary Outcome
Frequency and severity of AEs, laboratory abnormalities, and physical exam findings will be reported.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Cusatuzumab
Study Locations (20)
Other
- Universitaetsklinik Hamburg-Eppendorf - Hamburg
- Universitaetsklinikum Leipzig - Leipzig
- Klinikum der Universitaet Muenchen - München
- Szpital Uniwersytecki w Krakowie - Krakow
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi - Lodz
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Cornell Medicine - New York
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester - Rochester
Alberta
- Tom Baker Cancer Centre - Calgary
- University of Alberta Hospital - Edmonton
California
- City of Hope - Duarte
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Pennsylvania
- University of Pittsburgh School of Medicine - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2026-05-15 |
| Phase | Phase 1 |
What the registry record for NCT04150887 still lists
NCT04150887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 114-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT04150887 names 20 study sites across 12 states, led by Other, New York, Alberta.
Frequently Asked Questions
What is clinical trial NCT04150887 about?
NCT04150887 is a clinical study titled "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia". The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
What is the current status of trial NCT04150887?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-12-23. Estimated completion is 2026-05-15.
What conditions does trial NCT04150887 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT04150887?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Cusatuzumab (DRUG).
Who is sponsoring clinical trial NCT04150887?
This trial is sponsored by OncoVerity, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04150887 being conducted?
This trial has 20 study locations across California, Kentucky, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04150887's enrollment target sits among peer trials
61 17th of 30 higher than 14 of 30 other Leukemia, Myeloid, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia, Myeloid, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
RECRUITING · Phase 1
-
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
RECRUITING · Phase 1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI